Evidence map›Paper›PMID 41349560›Full record

ReviewAnnual review of immunology2026

CD8+ Regulatory T Cells.

Veena K Vuttaradhi, Clotilde M Vermelle, John Y Choi, Liqian Niu, Xiaolei Tang, Jamil R Azzi, Harvey Cantor

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annual review of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Regulatory CD8Nature immunology · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Veena K VuttaradhiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; email: harvey_cantor@dfci.harvard.edu.
Clotilde M VermelleDepartment of Biochemistry, University of Heidelberg, Heidelberg, Germany.
John Y ChoiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Liqian NiuDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; email: harvey_cantor@dfci.harvard.edu.
Xiaolei TangDepartment of Veterinary Biomedical Sciences, Lewyt College of Veterinary Medicine, Long Island University, Brookville, New York, USA.
Jamil R AzziDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Harvey CantorDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; email: harvey_cantor@dfci.harvard.edu.

Funding

IMMUNOLOGIC MECHANISMS THAT PREVENT AUTOIMMUNITYR01AI037562 · NIAID · DANA-FARBER CANCER INSTITUTE · PI CANTOR, HARVEY · 1996 to 2021
$9.4M
TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007527 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1986 to 2021
$8.8M
THE T-CELL RESPONSE TO ANTIGENR01AI048125 · NIAID · DANA-FARBER CANCER INSTITUTE · PI CANTOR, HARVEY · 2000 to 2021
$5.1M
The novel role of HLA-E restricted CD8 regulatory T cells in kidney allograft rejectionR01AI173307 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Jamil Azzi, HARVEY CANTOR · 2023 to 2026
$2.7M
Peptide-dependent mobilization of CD8 regulatory cells in cardiac transplantationR01AI165870 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI AZZI, JAMIL, CANTOR, HARVEY · 2023 to 2025
$2.7M
The novel role of the immunoproteasome subunit LMP7 in allo-immunity and T cell exhaustionR01AI134842 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI AZZI, JAMIL · 2018 to 2022
$1.9M
Enhancing the TCR-induced Response of HLA-E-restricted Regulatory CD8 T Cells to Promote Allograft ToleranceK08AI182491 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CHOI, JOHN YONGJOON · 2024 to 2025
$390k
NIAID NIH HHS K08 AI182491NIAID NIH HHS R01 AI037562NIAID NIH HHS R01 AI048125NIAID NIH HHS R01 AI134842NIAID NIH HHS R01 AI165870NIAID NIH HHS R01 AI173307NIDDK NIH HHS T32 DK007527
6 · The paper itself

Abstract

A wide variety of suppressive pathways have been investigated in efforts to understand the basis for immune tolerance. Although the contribution of CD4+ regulatory T cells (Tregs) to self-tolerance has been extensively studied, less attention has been given to CD8+ Tregs. Here we review recent insights into the development, function, and potential clinical applications of this regulatory subset. We focus on CD8+ Tregs that recognize self-peptides associated with MHC-Ib products and that express Ly49/KIR (killer cell immunoglobulin-like receptor) coinhibitory receptors. Recent analyses of their T cell receptor repertoire, thymic differentiation, and mechanism of suppression are summarized. Identification of the human homolog of these cells has suggested new strategies for CD8+ Treg-dependent immunotherapy for autoimmune disease and cancers.

Indexed as

CD8-Positive T-LymphocytesT-Lymphocytes, RegulatoryAnimalsAutoimmune DiseasesCell DifferentiationHumansImmune ToleranceImmunotherapyNeoplasmsReceptors, Antigen, T-CellSelf ToleranceReceptors, Antigen, T-CellHeliosHLA-EKIRLy49multiple sclerosisQa-1self-tolerance

Identifiers

PMID41349560
PMCPMC13354115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.